The EU In Vitro Diagnostics Regulation and Brexit loom large for UK IVD companies, but manufacturers serving the $1.6bn UK IVD market have many other competing concerns. It’s the most challenging period in more than 15 years, according to the British In Vitro Diagnostics Association Chief Executive Doris-Ann Williams.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced February-March 2014.

Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Venture Funding column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced January through February 2014.

Dynamic stabilization may sound like an oxymoron, but the concept is driving compound annual growth of more than 50% over the next decade in a new segment of the spine industry. The US market for spinal motion preserving and nonfusion products was worth approximately $186 million in 2004, and is projected to reach more than $1.5 billion in the year 2009, according to "US Markets for Spinal Motion Preserving Devices," a report just published by Windhover/Medtech Insight.